The comparative clinical pharmacology of vincristine and vindesine: Does vindesine offer any advantage in clinical use?-Reference-Cited by-同舟云学术

The comparative clinical pharmacology of vincristine and vindesine: Does vindesine offer any advantage in clinical use?

Published:1995-11 Issue:6 Volume:21 Page:513-525
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Joel Simon

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference75 articles.

1. The vinca alkaloids: a new class of oncolytic agents;Johnson;Cancer Res.,1963

2. New vinca alkaloids and related compounds;Budman;Semin. Oncol.,1992

3. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules;Himes;Pharmacol. Ther.,1991

4. Correlation of biologic data with physicochemical properties among the vinca alkaloids and their congeners;Owellen;Biochem. Pharmacol.,1977

5. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro;Jordan;Cancer Res.,1985

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Injectable polypeptide-polysaccharide depot for preventing postoperative tumor recurrence by concurrent in situ chemotherapy and brachytherapy;Materials Today Bio;2024-10

2. Vincristine-based nanoformulations: a preclinical and clinical studies overview;Drug Delivery and Translational Research;2023-08-08

3. Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges;3 Biotech;2023-05-24

4. Alkaloids as potential anticancer agent;Recent Frontiers of Phytochemicals;2023

5. Potential phytochemicals as microtubule-disrupting agents in cancer prevention;Recent Frontiers of Phytochemicals;2023